Condition
Cutaneous Ulcer
Total Trials
5
Recruiting
0
Active
0
Completed
4
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
0%
0 of 4 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (1)
P 3 (1)
Trial Status
Completed4
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT06730022UnknownPrimary
Dermacyte® Liquid for Treatment of Cutaneous Ulcers and Wounds
NCT05165628Phase 1Completed
Safety, Tolerability and Efficacy of CYP-006TK in Adults with Diabetic Foot Ulcers
NCT05764876Phase 3Completed
Repurposing Clinically Approved Drugs for Yaws with an Insight Into the Cutaneous Ulcer Disease Syndrome (Trep-AByaws)
NCT04453124Phase 2Completed
An Accessible Low-cost Plant Treatment for Cutaneous Ulcers
NCT04030832CompletedPrimary
Reconstruction of Skin Substance Loss With "Micro-grafts" Obtained by Mechanical Disintegration
Showing all 5 trials